We are a global team wholly dedicated to the study of cancer. As a demonstration of the promise and potential of our research, our pipeline currently includes more than 15 investigational candidates that address a wide range of cancers. Learn more about our pipeline.

We fully recognize that progress against cancer is a daunting task. Despite extensive effort in both the public and private sectors, curing cancer is likely to remain an elusive goal for some time to come. Yet we thrive on both the challenge and hope of doing our part to make that goal a reality.

Our focus is on compounds that are either unprecedented in their approach or offer a best-in-class advantage. We believe this higher-powered level of scientific endeavor is more than an exercise in "drug engineering." It demands personal determination on the part of our scientists and an intolerance of conventional wisdom.

Our oncology capabilities encompass both small molecule and antibody drugs so that we can select the most appropriate candidates to achieve the desired therapeutic effect. Our research and development (R&D) efforts are conducted through our scientific leadership at Takeda. Learn more about our R&D efforts.

We are excited by the possibilities, and driven forward by our sense of urgency to advance the care of cancer patients.


A protein substance produced by the immune system and found in the blood or tissues in response to a specific antigen, such as a bacterium or toxin.


Fundamental components of all living cells, including substances such as enzymes, hormones, and antibodies, thatare necessary for the proper functioning of an organism.

Small Molecule Drug

One or more active chemical compounds, typically formulated as an orally available pill, that interact with a specific biological target, such as a receptor, enzyme or ion channel, to provide a curative effect.